IMTX (Immatics NV) Interest Income : $25.1 Mil (TTM As of Sep. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immatics NV Interest Income?

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Immatics NV's interest income for the three months ended in Sep. 2024 was $6.1 Mil. Its interest income for the trailing twelve months (TTM) ended in Sep. 2024 was $25.1 Mil.

Immatics NV Interest Income Historical Data

The historical data trend for Immatics NV's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immatics NV Interest Income Chart

Immatics NV Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Income

Get a 7-Day Free Trial

0.88

1.03

0.15

2.62

15.10

Immatics NV Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Income	Get a 7-Day Free Trial															4.26	5.29	6.84	6.85	6.13

Immatics NV Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $25.1 Mil.

Immatics NV Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immatics NV (NAS:IMTX) » Definitions » Interest Income

Comparable Companies

Traded in Other Exchanges

4A3:Germany

Address

Paul-Ehrlich-Strasse 15, Tubingen, BW, DEU, 72076

Website

https://www.immatics.com

Immatics NV is a biotechnology company that is engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies.